Results 101 to 110 of about 8,557 (171)

Biosimilars in Pediatric IBD: Updated Considerations for Disease Management

Biologics: Targets & Therapy, 2022
Valeria Dipasquale, Ugo Cucinotta, Claudio Romano Pediatric Gastroenterology and Cystic Fibrosis Unit, Department of Human Pathology in Adulthood and Childhood “G.
Dipasquale V, Cucinotta U, Romano C
doaj  

Is CT-P13 As Effective As Infliximab In Controlling Pain In Adult Patients With Rheumatoid Arthritis? [PDF]

, 2020
OBJECTIVE: The objective of this selective EBM review is to determine whether or not CTP13 is as good as infliximab in controlling pain in adult patients with rheumatoid arthritis. STUDY DESIGN: A review of three double-blind randomized controlled trials
Nazareno, Emily
core   +1 more source

Clinical role, optimal timing and frequency of serum infliximab and anti-infliximab antibody level measurements in patients with inflammatory bowel disease [PDF]

, 2017
BACKGROUND: Serum infliximab (IFX) and antibody-to-infliximab (ATI) levels are objective parameters, that may have a great role in the therapeutic decisions during maintenance biological therapy. RESEARCH DESIGN AND METHODS: 48 inflammatory bowel disease
Bor Renáta, Bálint Anita, Farkas Klaudia, Fábián Anna, Matuz Mária, Milassin Ágnes, Molnár Tamás, Nagy Ferenc, Rutka Mariann, Szepes Zoltán   +9 more
core   +3 more sources

Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective

Therapeutic Advances in Gastroenterology, 2019
Background: Biological therapy has revolutionized the treatment of inflammatory bowel disease (IBD). After the expiration of patents for biological innovator products, development of biosimilars increased. CT-P13 was the first biosimilar approved for the
Ágnes Milassin, Anna Fábián, Tamás Molnár   +2 more
doaj   +1 more source

A new venue of TNF targeting [PDF]

, 2018
The first Food and Drug Administration-(FDA)-approved drugs were small, chemically-manufactured and highly active molecules with possible off-target effects, followed by protein-based medicines such as antibodies.
Libert, Claude, Steeland, Sophie, Vandenbroucke, Roosmarijn   +2 more
core   +1 more source

Analysis of real-world treatment patterns in a matched rheumatology population that continued innovator infliximab therapy or switched to biosimilar infliximab

Biologics: Targets & Therapy, 2018
Yusuf Yazici,1 Lin Xie,2 Adesuwa Ogbomo,2 Lorie A Ellis,3 Kavitha Goyal,4 Amanda Teeple,5 Ismail Simsek6 1Rheumatology, New York University, School of Medicine, New York, NY, USA; 2Health Economics and Outcomes Research, STATinMED Research, Ann Arbor, MI,
Yazici Y, Xie L, Ogbomo A, Ellis LA, Goyal K, Teeple A, Simsek I   +6 more
doaj  

A critical review of the United States regulatory pathways for determining the equivalence of efficacy between CT-P13 and original infliximab (Remicade®)

Drug Design, Development and Therapy, 2020
Soohyun Kim, 1, 2,* Siun Kim, 1, 2,* Howard Lee 1– 4 1Department of Transdisciplinary Studies, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea; 2Center for Convergence Approaches in Drug Development,
Kim S, Kim S, Lee H
doaj  

Update on biosimilars in inflammatory bowel disease: Position and recommendations in Mexico

Revista de Gastroenterología de México (English Edition), 2018
The biotechnology-derived medicines known as biosimilars are defined as non-originator treatments that have demonstrated quality, efficacy, and safety comparable to the reference biologic drug.
A. Mayoral-Zavala, A. Esquivel-Aguilar, C.M. del Real-Calzada, Y. Gutiérrez-Grobe, J. Ramos-García, J.L. Rocha-Ramírez, M.F. Rojas-Illanes, B. Rubio-Martínez, X. Sánchez-Chávez, J.K. Yamamoto-Furusho   +9 more
doaj   +1 more source

Actualización sobre los medicamentos biocomparables en la enfermedad inflamatoria intestinal: posición y recomendación en México

Revista de Gastroenterología de México, 2018
Resumen: Los medicamentos biotecnológicos biocomparables son definidos como tratamientos no innovadores que han demostrado calidad, eficacia y seguridad comparable al medicamento de referencia.
A. Mayoral-Zavala, A. Esquivel-Aguilar, C.M. del Real-Calzada, Y. Gutiérrez-Grobe, J. Ramos-García, J.L. Rocha-Ramírez, M.F. Rojas-Illanes, B. Rubio-Martínez, X. Sánchez-Chávez, J.K. Yamamoto-Furusho   +9 more
doaj   +1 more source

Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs : a systematic review and economic evaluation [PDF]

, 2017
BACKGROUND: Several biologic therapies are approved by the National Institute for Health and Care Excellence (NICE) for psoriatic arthritis (PsA) patients who have had an inadequate response to two or more synthetic disease-modifying antirheumatic drugs (
Adams, Adams, Ali, Anon, Antoni, Antoni, Antoni, Arthritis Foundation, Asaria, Askling, Atteno, Bansback, Baranauskaite, Bird, Bojke, Bowcock, Briggs, Brodszky, Capogrosso-Sansone, Carmona, Cawson, Centre for Reviews and Dissemination, Chang, Chen, Coates, Codreanu, Corbett, Corbett, Corbett, Craig, Cummins, Curtis, Department of Health (DH), Dias, Dias, Dias, Dixon, Dolan, Drummond, Eder, Einarson, Emery, European Medicines Agency, Fagerli, Fagerli, Fagerli, Felson, Galadari, Genovese, Girolomoni, Gladman, Gladman, Gladman, Glintborg, Glintborg, Glintborg, Gossec, Gottlieb, Gottlieb, Gottlieb, Gottlieb, GRAPPA, Gratacós, Haberhauer, Hartman, Helliwell, HM Treasury, Husted, Iannone, Joint Formulary Committee, Joint Formulary Committee, Julious, Kane, Karlsson, Kavanaugh, Kavanaugh, Kavanaugh, Kavanaugh, Kavanaugh, Kavanaugh, Kavanaugh, Kobelt, Kristensen, Krueger, Kyle, Langley, Lefebvre, Lefebvre, Leung, Leung, Madan, Maneiro, Mariette, McInnes, McInnes, Mease, Mease, Mease, Mease, Mease, Mease, Mease, Mease, Mease, Mease, Mease, Mease, Mease, Mease, Mease, Michelsen, Migliore, Moll, Morgan, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence (NICE), National Institute for Health and Care Excellence (NICE), Novartis Pharmaceuticals, Novartis Pharmaceuticals, Novartis Pharmaceuticals, Office for National Statistics, O’Connor, Picchianti-Diamanti, Poole, Poyner, Ramiro, Reveille, Ritchlin, Ritchlin, Rodgers, Ruderman, Saad, Saad, Salisbury NHS Foundation Trust, Schett, Shiel, Simard, Singh, Smith, Spiegelhalter, Sterry, Stolfa, Tarp, Taylor, Thaçi, Torii, Torre Alonso, Tzanetakos, Ungprasert, Wang, Wong, Wong, Yang, Yang, Yang, Zisman   +157 more
core   +2 more sources